-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

Benzinga·08/04/2026 13:18:40
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $285 to $300.